Rangeley Capital LLC Buys Shares of 320,000 Cardlytics, Inc. (NASDAQ:CDLX)

Rangeley Capital LLC purchased a new stake in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 320,000 shares of the company's stock, valued at approximately $1,187,000. Cardlytics accounts for approximately 1.1% of Rangeley Capital LLC's investment portfolio, making the stock its 28th largest position. Rangeley Capital LLC owned 0.63% of Cardlytics as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. RBF Capital LLC increased its stake in Cardlytics by 311.9% in the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company's stock worth $1,562,000 after buying an additional 369,620 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Cardlytics by 56.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company's stock valued at $1,016,000 after purchasing an additional 113,966 shares during the period. Geode Capital Management LLC lifted its holdings in Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company's stock worth $3,371,000 after purchasing an additional 73,484 shares in the last quarter. Barclays PLC lifted its holdings in Cardlytics by 223.9% in the 3rd quarter. Barclays PLC now owns 58,026 shares of the company's stock worth $186,000 after purchasing an additional 40,112 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Cardlytics in the 3rd quarter worth approximately $82,000. 68.10% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Cardlytics Trading Down 7.2 %

Shares of NASDAQ:CDLX traded down $0.11 during trading hours on Tuesday, hitting $1.35. 341,322 shares of the company's stock traded hands, compared to its average volume of 1,018,477. The firm has a market capitalization of $70.05 million, a P/E ratio of -0.22 and a beta of 1.39. The business has a fifty day moving average price of $2.58 and a 200-day moving average price of $3.31. Cardlytics, Inc. has a 1 year low of $1.24 and a 1 year high of $15.89. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Insider Activity at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 46,857 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $159,313.80. Following the transaction, the chief executive officer now directly owns 418,637 shares in the company, valued at $1,423,365.80. This trade represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Alexis Desieno sold 24,778 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total value of $84,245.20. Following the transaction, the chief financial officer now owns 140,948 shares in the company, valued at approximately $479,223.20. This represents a 14.95 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,172 shares of company stock worth $313,759 in the last quarter. 4.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CDLX shares. Lake Street Capital lowered their target price on shares of Cardlytics from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Thursday, March 13th. Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a research note on Thursday, March 13th. Finally, Evercore ISI dropped their price objective on shares of Cardlytics from $4.00 to $3.00 and set an "in-line" rating for the company in a research note on Thursday, March 13th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Cardlytics presently has a consensus rating of "Hold" and a consensus target price of $6.42.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.